Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to compare the safety and efficacy of USL-221 to placebo for postmenopausal patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Upsher-Smith Laboratories
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Postmenopausal women

• Have moderate to severe hot flashes

• Normal Pap Smear

Exclusion Criteria:

• Abnormal mammogram

• Abnormal clinical breast exam

• BMI >35